

MIST ULTRASOUND THERAPY RCT DUE TO START

NICE have recently released a press release detailing the first clinical trial resulting from NICE medical technology guidance recommendations which is due to start on the MIST ultrasound wound healing device for chronic wounds.

Full details on the RCT, which will be undertaken independently, may be accessed on:

<http://www.nice.org.uk/newsroom/pressreleases/NICERecommendedClinicalTrialDueToStartOnPromisingWoundHealingDevice.jsp> . The 2011 NICE guidance, ‘MIST Therapy system for the promotion of wound healing in chronic and acute wounds’, which encouraged further research into the device is available at <http://guidance.nice.org.uk/MTG5> .

In a separate development, the NHS Technology Adoption Centre (NTAC) is about to release a briefing pack that has been produced on MIST due to be circulated to NHS staff which illustrated findings from **Ray Norris** (Clinical Nurse Specialist – Tissue Viability) North East London NHS Foundation Trust. This NTAC briefing is not connected with the NICE guidance or the independent clinical trial.

Ray Norris said: “One of the main benefits of the MIST technology is in the ability to be able to establish a clear clinical pathway for patients who have exhausted all existing methods of wound treatment. Having the MIST technology available as an additional method of wound treatment provides a further option for patients with hard to heal wounds where previously these patients may have been consigned to prolonged wound management, impacting upon their quality of life.”

MIST is manufactured by Celleration Ltd and distributed exclusively in the UK via H&R Healthcare.

For further information please contact: Maria Silabon, Business Development Manager on : 07891 711823 or maria.silabon@hrhealthcare.co.uk